Table 3 Effect of type of anaesthesia on the efficacy and safety of dabigatran etexilate: event rates observed with the different types of anaesthesia for each therapy

Dabigatran etexilate 220 mg

 Major VTE and VTE-related mortality

4.0% (23/578)

2.7% (29/1080)

2.7% (10/369)

  OR (95% CI) versus general anaesthesia

0.67 (0.37–1.22)

0.67 (0.28–1.49)

 MBE

0.9% (7/785)

1.7% (24/1379)

1.4% (7/497)

  OR (95% CI) versus general anaesthesia

1.97 (0.82–5.43)

1.59 (0.47–5.34)

 MBE/CRBE

4.8% (38/785)

5.9% (81/1379)

6.0% (30/497)

  OR (95% CI) versus general anaesthesia

1.23 (0.82–1.87)

1.26 (0.74–2.12)

Dabigatran etexilate 150 mg

 Major VTE and VTE-related mortality

5.1% (30/587)

3.2% (35/1082)

3.3% (13/395)

  OR (95% CI) versus general anaesthesia

0.62 (0.37–1.06)

0.63 (0.30–1.27)

 MBE

1.3% (10/781)

1.0% (14/1403)

0.8% (4/530)

  OR (95% CI) versus general anaesthesia

0.78 (0.32–1.97)

0.59 (0.13–2.05)

 MBE/CRBE

5.4% (42/781)

5.4% (76/1403)

6.6% (35/530)

  OR (95% CI) versus general anaesthesia

1.01 (0.67–1.52)

1.24 (0.76–2.03)

Enoxaparin

 Major VTE and VTE-related mortality

3.5% (20/566)

3.2% (37/1143)

3.1% (12/383)

  OR (95% CI) versus general anaesthesia

0.91 (0.51–1.68)

0.88 (0.39–1.92)

 MBE

1.3% (10/745)

1.5% (21/1430)

1.6% (8/512)

  OR (95% CI) versus general anaesthesia

1.10 (0.49–2.62)

1.17 (0.40–3.31)

 MBE/CRBE

4.6% (34/745)

5.6% (80/1430)

4.5% (23/512)

  OR (95% CI) versus general anaesthesia

1.24 (0.81–1.93)

0.98 (0.55–1.74)